Hemostatic Powder for Non‐Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
In patients with non-malignant NVUGIB, HP demonstrated lower risk of further bleeding during EGD in cases with non-bleeding visible vessels. There was no statistically significant difference in further bleeding during EGD for active bleeding, nor in rebleeding risk at 1, 3, 7, 15, or 30 days.
Authors
- Fauze Maluf‐Filho (ORCID: https://orcid.org/0000-0001-8875-420X)
- Gilmara Coelho Meine (ORCID: https://orcid.org/0000-0001-5389-4368)
- Fernanda Pessorrusso (ORCID: https://orcid.org/0000-0002-6530-4940)
- Renan Martins Gomes Prado (ORCID: https://orcid.org/0000-0001-7836-067X)
- Mohammad Bilal (ORCID: https://orcid.org/0000-0002-1784-212X)
- Paula Santo
Institutions
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Texas Tech University (US)
- Cleveland Clinic (US)
- Universidade Feevale (BR)
- Cleveland Foundation (US)
- Instituto do Câncer do Estado de São Paulo (BR)
- University of Colorado Anschutz Medical Campus (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-01-23
- DOI
- https://doi.org/10.1111/jgh.70249
- Primary Topic
- Gastrointestinal Bleeding Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00